| Autor: |
Fu T; Medical Molecular Diagnostics Key Laboratory of Guangdong, Dongguan 523808, China.; Department of Biochemistry and Molecular Biology and Department of Clinical Biochemistry in Guangdong Medical University, Dongguan 523808, China., Liang A; Medical Molecular Diagnostics Key Laboratory of Guangdong, Dongguan 523808, China.; Department of Clinical Laboratory Biochemistry of Guangdong Medical University, Dongguan 523808, China., Liu Y; Medical Molecular Diagnostics Key Laboratory of Guangdong, Dongguan 523808, China.; Department of Biochemistry and Molecular Biology and Department of Clinical Biochemistry in Guangdong Medical University, Dongguan 523808, China. |
| Jazyk: |
čínština |
| Zdroj: |
Zhongguo fei ai za zhi = Chinese journal of lung cancer [Zhongguo Fei Ai Za Zhi] 2020 Jul 20; Vol. 23 (7), pp. 597-602. Date of Electronic Publication: 2020 May 21. |
| DOI: |
10.3779/j.issn.1009-3419.2020.101.16 |
| Abstrakt: |
Lung cancer is the most common malignant tumor in the world with the highest incidence of deaths. In recent years, the treatment of lung cancer has made a significant breakthrough. However, as the tumor progresses, lung cancer cells inevitably acquire resistance and the efficacy of the treatment are greatly reduced. P21 protein plays a dual role in tumors, which not only regulates the cell cycle, induces apoptosis, inhibits cell proliferation, but also protects cells against apoptosis and promotes tumor cell resistance. This article reviews the research on P21 and lung cancer resistance, to provide new ideas for individualized treatment of lung cancer and overcoming lung cancer resistance. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
